J&J Focusing On “Product Solutions”; Diabetes Care May Be Early Model
Executive Summary
Johnson & Johnson is moving towards a business model focused on offering "product solutions" for the health care system, Biopharmaceuticals Group Chairman Joseph Scodari told the Wharton Health Care Business Conference Feb. 19 in Philadelphia
You may also be interested in...
J&J Sees Rx Synergies In Guidant Deal; Big Buy Does Not Rule Out More Deals
J&J's acquisition of Guidant will open up new areas of opportunity for collaboration between the pharmaceutical, device and diagnostic operations of the company, CEO William Weldon declared during a Dec. 16 analysts conference call
J&J Sees Rx Synergies In Guidant Deal; Big Buy Does Not Rule Out More Deals
J&J's acquisition of Guidant will open up new areas of opportunity for collaboration between the pharmaceutical, device and diagnostic operations of the company, CEO William Weldon declared during a Dec. 16 analysts conference call
J&J Ready To Re-Balance? Guidant Deal Would Decrease Dependence On Rx
Johnson & Johnson's proposed acquisition of Guidant will help the company restore the balance in its health care portfolio